Joel Embiid: Everything you need to know

Joel Embiid

#21 C

Philadelphia 76ers

Status

GTD - Ankle Expected Return: 2026-05-08

STATS

Career Averages

PTS

REB

AST

BLK

STL

27.6

10.8

3.7

1.6

0.9

Year	GP	GS	MIN	PTS	REB	AST	BLK	STL	TO	DD2	TD3	3PM	3PA	3P%	2PM	2PA	2P%	FGM	FGA	FG%	FTM	FTA	FT%	OREB	DREB	PF	A/TO	+/-	TS%
2025-26	38	38	31.6	26.9	7.7	3.9	1.2	0.6	2.9	10	1	1.4	4.2	33.3%	7.6	14.2	53.5%	9.0	18.3	48.9%	7.5	8.8	85.4%	2.0	5.7	2.2	1.4	+155	60.5%
2024-25	19	19	30.2	23.8	8.2	4.5	0.9	0.7	3.3	7	1	1.2	4.1	29.9%	6.2	12.5	49.2%	7.4	16.6	44.4%	7.8	8.9	88.2%	1.9	6.3	2.2	1.4	-57	58.0%
2023-24	39	39	33.6	34.7	11.0	5.6	1.7	1.2	3.8	30	2	1.4	3.6	38.8%	10.2	18.3	55.6%	11.5	21.8	52.9%	10.2	11.6	88.3%	2.4	8.6	2.9	1.5	+267	64.4%
2022-23	66	66	34.6	33.1	10.2	4.2	1.7	1.0	3.4	39	1	1.0	3.0	33.0%	10.0	17.1	58.7%	11.0	20.1	54.8%	10.0	11.7	85.7%	1.7	8.4	3.1	1.2	+424	65.5%
2021-22	68	68	33.8	30.6	11.7	4.2	1.5	1.1	3.1	46	2	1.4	3.7	37.1%	8.4	15.9	52.9%	9.8	19.6	49.9%	9.6	11.8	81.4%	2.1	9.6	2.7	1.3	+367	61.6%
2020-21	51	51	31.1	28.5	10.6	2.8	1.4	1.0	3.1	31	0	1.1	3.0	37.7%	7.9	14.6	54.1%	9.0	17.6	51.3%	9.2	10.7	85.9%	2.2	8.4	2.4	0.9	+405	63.6%
2019-20	51	51	29.5	23.0	11.6	3.0	1.3	0.9	3.1	37	0	1.1	3.4	33.1%	6.4	12.3	51.7%	7.5	15.7	47.7%	6.9	8.5	80.7%	2.8	8.9	3.4	1.0	+163	59.0%
2018-19	64	64	33.7	27.5	13.6	3.7	1.9	0.7	3.5	58	2	1.2	4.1	30.0%	7.8	14.6	53.5%	9.1	18.7	48.4%	8.2	10.1	80.4%	2.5	11.1	3.3	1.0	+371	59.3%
2017-18	63	63	30.4	22.9	11.0	3.2	1.8	0.6	3.7	38	0	1.0	3.4	30.8%	7.0	13.4	52.7%	8.1	16.8	48.3%	5.7	7.4	76.9%	2.3	8.7	3.3	0.9	+484	57.3%
2016-17	31	31	25.4	20.2	7.8	2.1	2.5	0.9	3.8	0	0	1.2	3.2	36.7%	5.3	10.7	49.5%	6.5	13.8	46.6%	6.2	7.9	78.3%	2.0	5.9	3.6	0.6	+0	58.4%
Career	490	490	31.9	27.6	10.8	3.7	1.6	0.9	3.4	296	9	1.2	3.5	33.9%	7.9	14.7	53.9%	9.1	18.2	50.0%	8.3	9.9	83.0%	2.2	8.6	3.0	1.1	+2579	61.3%

Career Averages

PTS

REB

AST

BLK

STL

24.9

10.6

3.3

1.6

0.8

Year	GP	GS	MIN	PTS	REB	AST	BLK	STL	TO	DD2	TD3	3PM	3PA	3P%	2PM	2PA	2P%	FGM	FGA	FG%	FTM	FTA	FT%	OREB	DREB	PF	A/TO	+/-	TS%
2025-26	5	5	34.2	25.2	8.0	5.8	0.6	0.4	1.8	3	0	0.6	4.4	13.6%	7.8	15.4	50.6%	8.4	19.8	42.4%	7.8	9.2	84.8%	1.2	6.8	2.2	3.2	-18	52.8%
2023-24	6	6	41.3	33.0	10.8	5.7	1.5	1.2	4.2	4	1	2.2	6.5	33.3%	7.7	15.7	48.9%	9.8	22.2	44.4%	11.2	13.0	85.9%	3.2	7.7	3.3	1.4	+46	59.2%
2022-23	9	9	37.3	23.7	9.8	2.7	2.8	0.7	3.9	5	0	0.6	3.1	17.9%	6.8	13.9	48.8%	7.3	17.0	43.1%	8.4	9.3	90.5%	1.8	8.0	3.0	0.7	-6	56.1%
2021-22	10	10	38.5	23.6	10.7	2.1	0.8	0.4	3.2	8	0	0.7	3.3	21.2%	7.1	12.8	55.5%	7.8	16.1	48.4%	7.3	8.9	82.0%	2.1	8.6	3.4	0.7	+28	59.0%
2020-21	11	11	32.5	28.1	10.5	3.4	1.5	1.0	3.8	5	0	1.5	3.7	39.0%	7.7	14.2	54.5%	9.2	17.9	51.3%	8.3	9.9	83.5%	1.5	9.1	3.0	0.9	+121	63.1%
2019-20	4	4	36.3	30.0	12.3	1.3	1.3	1.5	3.8	4	0	1.0	4.0	25.0%	7.5	14.5	51.7%	8.5	18.5	45.9%	12.0	14.8	81.4%	2.8	9.5	4.5	0.3	-53	60.0%
2018-19	11	11	30.4	20.2	10.5	3.4	2.3	0.7	3.6	7	0	1.1	3.5	30.8%	5.1	10.9	46.7%	6.2	14.5	42.8%	6.7	8.2	82.2%	1.9	8.5	3.1	0.9	+143	55.9%
2017-18	8	8	34.8	21.4	12.6	3.0	1.8	0.9	3.6	7	0	1.0	3.6	27.6%	6.5	13.6	47.7%	7.5	17.3	43.5%	5.4	7.6	70.5%	2.9	9.8	3.9	0.8	+43	51.9%
Career	64	64	35.2	24.9	10.6	3.3	1.6	0.8	3.5	43	1	1.1	3.9	27.5%	6.9	13.5	50.7%	7.9	17.4	45.6%	8.0	9.6	83.0%	2.1	8.6	3.3	0.9	+304	57.6%

Regular Season
Date	Opp	Result	MIN	PTS	REB	AST	BLK	STL	TO	3PA	3PM	3P%	2PA	2PM	2P%	FGA	FGM	FG%	FTA	FTM	FT%	OREB	DREB	A/TO	+/-	PF	PER	TS%
4/6	SAS	L 115-102	39	34	12	1	4	0	4	6	2	33.3%	13	6	46.2%	19	8	42.1%	19	16	84.2%	5	7	0.3	-7	3	40	62.1%
4/3	MIN	W 115-103	34	19	13	7	3	0	1	6	1	16.7%	11	5	45.5%	17	6	35.3%	7	6	85.7%	2	11	7.0	+15	3	29	47.3%
3/30	MIA	L 119-109	34	26	7	3	1	0	3	6	2	33.3%	19	8	42.1%	25	10	40.0%	5	4	80.0%	1	6	1.0	-18	4	15	47.8%
3/28	CHA	W 118-114	35	29	6	2	2	0	0	6	3	50.0%	13	5	38.5%	19	8	42.1%	13	10	76.9%	0	6	0.0	+5	0	33	58.7%
3/25	CHI	W 157-137	28	35	6	7	1	0	3	3	3	100.0%	14	9	64.3%	17	12	70.6%	9	8	88.9%	0	6	2.3	+33	2	44	83.5%
2/26	MIA	W 124-117	31	26	11	4	0	1	2	6	2	33.3%	14	6	42.9%	20	8	40.0%	9	8	88.9%	1	10	2.0	+0	1	32	54.3%
2/24	IND	W 135-114	26	27	6	5	1	0	4	4	1	25.0%	13	10	76.9%	17	11	64.7%	5	4	80.0%	1	5	1.3	-1	2	30	70.3%
2/7	PHX	W 109-103	33	33	9	3	1	0	2	7	4	57.1%	12	5	41.7%	19	9	47.4%	13	11	84.6%	1	8	1.5	-10	3	35	66.7%
2/5	LAL	L 119-115	38	35	7	7	2	1	3	2	1	50.0%	17	12	70.6%	19	13	68.4%	8	8	100.0%	1	6	2.3	+7	2	49	77.7%
2/2	LAC	W 128-113	32	24	5	3	0	1	1	2	1	50.0%	17	7	41.2%	19	8	42.1%	7	7	100.0%	0	5	3.0	+2	4	22	54.3%
1/31	NOP	W 124-114	39	40	11	4	2	1	5	5	3	60.0%	22	10	45.5%	27	13	48.1%	14	11	78.6%	4	7	0.8	+16	2	38	60.3%
1/29	SAC	W 113-111	35	37	5	8	1	1	2	2	1	50.0%	19	12	63.2%	21	13	61.9%	13	10	76.9%	0	5	4.0	+9	3	44	69.2%
1/27	MIL	W 139-122	29	29	9	5	0	1	2	4	1	25.0%	20	10	50.0%	24	11	45.8%	6	6	100.0%	6	3	2.5	+6	2	27	54.4%
1/24	NYK	L 112-109	36	38	11	5	1	0	4	5	3	60.0%	16	10	62.5%	21	13	61.9%	12	9	75.0%	3	8	1.3	-3	2	45	72.3%
1/22	HOU	W 128-122	45	32	15	10	1	1	5	3	1	33.3%	16	9	56.3%	19	10	52.6%	12	11	91.7%	3	12	2.0	+21	1	53	65.9%
1/19	IND	W 113-104	33	30	9	4	0	0	1	1	1	100.0%	16	9	56.3%	17	10	58.8%	10	9	90.0%	2	7	4.0	+3	1	38	70.1%
1/16	CLE	L 117-115	33	33	5	3	1	0	1	3	2	66.7%	19	8	42.1%	22	10	45.5%	12	11	91.7%	3	2	3.0	+9	0	34	60.5%
1/14	CLE	L 133-107	24	20	4	3	1	1	6	5	2	40.0%	9	5	55.6%	14	7	50.0%	4	4	100.0%	2	2	0.5	-18	0	17	63.5%
1/12	TOR	W 115-102	35	27	8	4	0	2	7	6	1	16.7%	11	8	72.7%	17	9	52.9%	8	8	100.0%	2	6	0.6	+12	1	28	65.8%
1/9	ORL	W 103-91	31	22	9	3	1	1	4	3	0	0.0%	14	7	50.0%	17	7	41.2%	9	8	88.9%	3	6	0.8	+4	2	23	52.5%
1/7	WAS	W 131-110	25	28	7	2	2	0	2	2	1	50.0%	12	9	75.0%	14	10	71.4%	8	7	87.5%	0	7	1.0	+27	3	33	79.9%
1/5	DEN	L 125-124	40	32	10	2	1	0	6	4	1	25.0%	18	12	66.7%	22	13	59.1%	5	5	100.0%	6	4	0.3	+8	2	32	66.1%
1/3	NYK	W 130-119	33	26	10	5	0	0	3	1	0	0.0%	14	9	64.3%	15	9	60.0%	12	8	66.7%	2	8	1.7	+9	4	31	64.1%
1/1	DAL	W 123-108	35	22	4	6	1	0	2	3	0	0.0%	15	9	60.0%	18	9	50.0%	5	4	80.0%	0	4	3.0	+9	1	25	54.5%
12/30	MEM	W 139-136	38	34	10	8	2	1	4	6	1	16.7%	22	10	45.5%	28	11	39.3%	12	11	91.7%	5	5	2.0	-5	5	34	51.1%
12/26	CHI	L 109-102	32	31	5	1	1	0	2	4	2	50.0%	15	8	53.3%	19	10	52.6%	9	9	100.0%	1	4	0.5	+2	2	29	67.5%
12/23	BKN	L 114-106	31	27	6	4	2	0	3	1	1	100.0%	12	7	58.3%	13	8	61.5%	12	10	83.3%	1	5	1.3	+1	5	33	73.9%
12/14	ATL	L 120-117	30	22	14	1	2	1	3	3	1	33.3%	17	7	41.2%	20	8	40.0%	6	5	83.3%	6	8	0.3	-8	2	27	48.6%
12/12	IND	W 115-105	31	39	9	3	0	1	3	8	2	25.0%	15	10	66.7%	23	12	52.2%	18	13	72.2%	2	7	1.0	+16	3	38	63.1%
12/7	LAL	L 112-108	30	16	7	2	1	1	0	6	0	0.0%	15	4	26.7%	21	4	19.0%	8	8	100.0%	2	5	0.0	+11	1	12	32.6%
12/4	GSW	W 99-98	25	12	6	3	1	0	3	5	0	0.0%	8	5	62.5%	13	5	38.5%	2	2	100.0%	0	6	1.0	+2	1	11	43.2%
11/30	ATL	L 142-134	30	18	4	2	1	1	2	3	0	0.0%	11	6	54.5%	14	6	42.9%	8	6	75.0%	1	3	1.0	-11	2	16	51.4%
11/8	TOR	W 130-120	25	29	6	4	1	0	2	4	1	25.0%	12	9	75.0%	16	10	62.5%	9	8	88.9%	2	4	2.0	+15	3	35	72.6%
11/4	CHI	L 113-111	25	20	6	2	4	3	3	6	1	16.7%	15	6	40.0%	21	7	33.3%	6	5	83.3%	2	4	0.7	+1	2	17	42.3%
10/31	BOS	L 109-108	25	20	6	3	2	0	4	2	1	50.0%	11	5	45.5%	13	6	46.2%	7	7	100.0%	1	5	0.8	+2	2	24	62.2%
10/28	WAS	W 139-134	23	25	7	5	1	0	3	6	3	50.0%	11	6	54.5%	17	9	52.9%	6	4	66.7%	3	4	1.7	+9	4	24	63.6%
10/25	CHA	W 125-121	20	20	2	4	0	2	4	6	3	50.0%	5	4	80.0%	11	7	63.6%	5	3	60.0%	0	2	1.0	-2	0	23	75.8%
10/22	BOS	W 117-116	20	4	6	2	1	0	0	4	0	0.0%	5	1	20.0%	9	1	11.1%	2	2	100.0%	1	5	0.0	-16	2	4	20.2%
Regular Season Totals			31.6	26.9	7.7	3.9	1.2	0.6	2.9	4.2	1.4	33.3%	14.2	7.6	53.5%	18.3	9.0	48.9%	8.8	7.5	85.4%	2.0	5.7	1.4	+155	2.2	32.8	60.5%

Postseason
Date	Opp	Result	MIN	PTS	REB	AST	BLK	STL	TO	3PA	3PM	3P%	2PA	2PM	2P%	FGA	FGM	FG%	FTA	FTM	FT%	OREB	DREB	A/TO	+/-	PF	PER	TS%
5/4	NYK	L 137-98	24	14	4	1	0	0	1	2	0	0.0%	9	3	33.3%	11	3	27.3%	9	8	88.9%	0	4	1.0	-24	1	14	46.8%
5/2	BOS	W 109-100	39	34	12	6	1	0	1	4	1	25.0%	22	11	50.0%	26	12	46.2%	11	9	81.8%	2	10	6.0	+11	2	45	55.1%
4/30	BOS	W 106-93	34	19	10	8	0	1	1	5	1	20.0%	13	5	38.5%	18	6	33.3%	7	6	85.7%	1	9	8.0	+7	2	26	45.1%
4/28	BOS	W 113-97	38	33	4	8	1	0	3	5	0	0.0%	18	12	66.7%	23	12	52.2%	10	9	90.0%	1	3	2.7	+13	4	32	60.2%
4/26	BOS	L 128-96	34	26	10	6	1	1	3	6	1	16.7%	15	8	53.3%	21	9	42.9%	9	7	77.8%	2	8	2.0	-25	2	33	52.1%
Postseason Totals			34.2	25.2	8.0	5.8	0.6	0.4	1.8	4.4	0.6	13.6%	15.4	7.8	50.6%	19.8	8.4	42.4%	9.2	7.8	84.8%	1.2	6.8	3.2	-18	2.2	33.2	52.8%

Joel Embiid: Breaking News

Embiid (ankle) is questionable for Friday's Game 3 of the Eastern Conference Semifinals against New York. The team mentioned after Game 2 that Embiid would be considered day-to-day moving forward, so this questionable tag aligns with this previous report. Philadelphia should have a better idea of Embiid's availability for Game 3 after watching him take part in shootaround and warmups.

Head coach Nick Nurse said Wednesday that Embiid will be day-to-day going forward with his ankle and hip injuries, per Tim Bontemps of ESPN.com. Embiid is out for Game 2 of the Eastern Conference Semifinals against the Knicks on Wednesday, but it sounds like he has a chance to return when the series shifts to Philadelphia on Friday for Game 3. Andre Drummond and Adem Bona are the prime candidates to start at center for the 76ers on Wednesday.

Embiid (ankle/hip) is out for Game 2 of the Eastern Conference Semifinals against the Knicks on Wednesday, Shams Charania of ESPN reports. This comes as a huge surprise after Embiid initially carried a probable tag. Charania notes that Embiid is dealing with ankle and hip issues, and it appears as though the fatigue from the opening-round win against Boston is catching up to him, as he was unable to participate in Wednesday's morning shootaround. The 76ers may now lean more on Andre Drummond and Adem Bona at center, but it's also possible the team relies on some small-ball lineups.